UK approval for Pfizer’s JAK inhibitor Cibinqo
Treatment approved for adults and adolescents with moderate to severe atopic dermatitis
Read More
Tag: abrocitinib
Patients gain early access to Pfizer’s atopic dermatitis drug
The MHRA has issued a positive scientific opinion for abrocitinib allowing its use via the early access to medicines scheme (EAMS)
Read More
Pfizer’s abrocitinib scores another phase III win in atopic dermatitis
JADE REGIMEN study investigated JAK1 inhibitor in moderate to severe atopic dermatitis
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
